Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring
NCT ID: NCT00399854
Last Updated: 2006-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
45 participants
INTERVENTIONAL
2006-03-31
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients were treated by endermologie device. Mechanical massage were performed for 12 weeks in a total of 24 treatment sessions: twice a week.
A set of photographs were took at visit 1 (baseline), visit 2, 3 and 4 with standardized positions and lighting conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dhermia® - Industra Mecânica Fina Ltda
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects agreeing to take part of all procedures of the study (including mechanical massage, photographs), after being fully informed on the objectives and nature of the investigations;
3. Female subjects between 25-45 years;
4. Subjects presenting with cellulite grades I-III on buttocks and thighs;
5. Medical history and physical examination which, based on the investigator's opinion, do not prevent the patient from taking part in the study and use the device under investigation;
6. Female subjects of childbearing age should present a negative urine pregnancy test and should be using an effective contraceptive method (3 months before the enrollement untill the end of the study);
7. Body Mass Index (BMI = weight/height2) beetwen 20,0-25,0 and 25,0-29,9;
8. Availability of the subject throughout the duration of the study (90 days);
9. Availability of the subject in maintaining a stable weight during the study (variation less than 2 kg)
10. Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol.
Exclusion Criteria
2. BMI superior 30,0;
3. Subjects with diabetes mellitus, cardiac insufficiency, asthma, or bronchitis;
4. Subjects participating in other clinical trials;
5. Subjects with neoplastic disorders, uncontrolled thyroid disorders or uncontrolled hypertension;
6. Subjects with coagulation disorders, using anticoagulants or tendency of bruises;
7. Subjects with vascular disorders (phlebitis or varicose veins) in the area to be treated;
8. Any prior aesthetic surgery affecting the area to be treated (liposuction, Subcision®), 3 months before the study, that may interfere with results;
9. Any other prior anti-cellulite treatment or body measures treatment, 30 days prior to the study;
10. Subjects with inflammation or active infection in the area to be treated.
11. Subjects with a history of adverse effects, which in the investigator's opinion should prevent the patient from participating in the study;
12. Patients with cutaneous or vascular alterations, that difficult visualization and documentation of cellulite;
13. Subjects with a history of medical treatment non-adherence or showing unwillingness to adhere to the study protocol;
14. Subjects who can not come to the visits (one missing visit/ month is allowed);
15. Subjects intending to initiate any intensive sport;
16. Subjects using analgesics, non-hormonal antiinflammatories, antihistaminics, corticosteroids, or diuretics;
17. Subjects tanned, or intending to expose the area of study to sun, artificial UV, or self-tanning during the study;
18. Any condition that, in the opinion of the investigator, can compromise the evaluation of the study.
25 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brazilan Center for Studies in Dermatology
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Doris Hexsel, MD
Role: STUDY_DIRECTOR
Brazilan Center for Studies in Dermatology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02CBED0501
Identifier Type: -
Identifier Source: org_study_id